Back to homepage

Musculoskeletal disease

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Authors: Martina Biggioggero MD, Andrea Becciolini MD, Chiara Crotti MD, Elena Agape MD, Ennio Giulio Favalli MD

This narrative review discusses the rationale for JAK inhibition in RA, with a special focus on the role of JAK1 selective blockade and a detailed description of available data from the results of clinical trials on upadacitinib and filgotinib.

More

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout

Authors: Fernando Pérez-Ruiz MD, PhD, Tim Jansen MD, Anne-Katrin Tausche MD, Mónica Juárez-Campo BSc, Ravichandra Karra Gurunath MD, Pascal Richette MD, PhD

The review aims to review current evidence about the efficacy and safety of lesinurad in combination with xanthine oxidase inhibitors in the treatment of hyperuricemia in patients with gout.

More

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports

Authors: José Alexandre Mendonça PhD, Guilherme B Damian MD

This series of case reports demonstrates the
efficacy of certolizumab pegol in patients with rheumatoid arthritis using gray scale
and power Doppler ultrasonography to monitor disease progression.

More

Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countries

Authors: Daniela Opris-Belinski MD, PhD, Shandor F Erdes MD, PhD, Simeon Grazio MD, PhD, Ladislav Šenolt MD, PhD, Maja Hojnik MD, PhD, Orsolya Nagy MD, PhD, Diana Marina BSc, Sándor Szántó MD, PhD, DSc

This study assessed the impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis in five Central and Eastern Europe countries.

More

The biosimilars journey: current status and ongoing challenges

Authors: Igor Age Kos MD, Valderílio Feijó Azevedo MD, PhD, Daniel Egg Neto, Sérgio Cândido Kowalski MD, PhD

Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.

More